Form 4: Actuate Therapeutics CFO Paul Lytle Receives Stock Options Upon IPO

Paul Lytle, CFO of Actuate Therapeutics, was granted 234,971 stock options following the company's initial public offering on August 14, 2024.

Summary

• Paul Lytle, the Chief Financial Officer of Actuate Therapeutics, received 234,971 non-qualified stock options on August 14, 2024.
• These options were granted upon the closing of Actuate Therapeutics' initial public offering (IPO).
• 25% of the options will vest on June 1, 2025.
• The remaining 75% of the options will vest in equal monthly installments over the subsequent 36 months following June 1, 2025.
• The options expire on August 14, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and aligns management with shareholder interests. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment and performance.

Future Outlook

The vesting schedule suggests a focus on long-term value creation and retention of key personnel.

Industry Context

Stock option grants are a common practice for incentivizing executives, especially following an IPO. This aligns management's interests with shareholders and encourages long-term growth.

Comparison to Industry Standards

• Stock option grants to executives are a standard practice in the pharmaceutical and biotechnology industries, particularly after an IPO.
• Companies like Moderna and BioNTech also issued significant stock options to their executives following major milestones, including their IPOs and the development of their COVID-19 vaccines.
• The vesting schedules are also typical, with many companies using a combination of cliff vesting (like the 25% on June 1, 2025) and subsequent monthly vesting to ensure continued commitment.

Stakeholder Impact

• Shareholders: Aligns management's interests with shareholder value creation.
• Employees: May improve morale by demonstrating confidence in the company's future.

Key Dates